New York, United States
OWKIN is a pioneering company at the intersection of AI and Biotechnology, founded in 2016 and headquartered in the United States. It positions itself as the first closed-loop AI generative biology firm, striving to set a new standard in biological reasoning. By developing the first BASI to revolutionize therapies, diagnostics, and rejuvenation, OWKIN aims to transform humanity's understanding and engineering of biology.
The company's distinctive strength lies in its ability to create large-scale reasoning models trained on patient-level multimodal data with real biological feedback. This closed-loop system, underpinned by exclusive partnerships with renowned hospitals and unique datasets, gives OWKIN a competitive edge akin to the data moats of other leading AI firms.
Having secured a $33.00M late-stage venture capital investment as of 01 March 2026, with backing from investors like Alpha Intelligence Capital, Karista, OTB Ventures, Sista Fund, and Serena, OWKIN is well-positioned as a potential leader in the field of general-purpose biology intelligence.
